Montelukast and Churg-Strauss syndrome

Swiss Medical Weekly

Volumn 134, Issue 25-26, 2004, Pages 377-380

  Conen, David ^a,b   Leuppie, Jörg ^a   Bubendorf, Lukas ^a   Ronsdorf, Anke ^a   Tamm, Michael ^a   Hauser, Thomas ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b KANTONSSPITAL BASEL   (Switzerland)

Author keywords

Asthma; Churg Strauss syndrome; Eosinophilia; Leukotriene receptor antagonists; Vasculitis

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHYLPREDNISOLONE; MONTELUKAST; PRANLUKAST; PREDNISONE; SALBUTAMOL; ZAFIRLUKAST;

ADULT; AIRWAY OBSTRUCTION; ARTICLE; ASTHMA; CASE REPORT; CHURG STRAUSS SYNDROME; CLINICAL FEATURE; DISEASE SEVERITY; DRUG EFFECT; DRUG MEGADOSE; DRUG SAFETY; EOSINOPHIL; HEART FAILURE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LUNG INFILTRATE; LUNG LAVAGE; MALE; MYOCARDITIS; OPEN LUNG BIOPSY; PATHOPHYSIOLOGY; SYMPTOM; THORAX RADIOGRAPHY;

EID: 4043063577     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Noth I, Strek ME, Leff AR. Churg-Strauss syndrome. Lancet 2003; 361:587-94.
2. Guillevin L, Lhote F, Gayraud M, Cohen P, Jarrousse B, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prognostic study in 342 patients. Medicine 1996; 75:17-28.
3. Wechsler ME, Garpestad E, Flier SR, Kocher O, Weiland DA, et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA 1998; 279:455-7.
4. Wechsler ME, Finn D, Gunawardena D, Westlake R, Barker A, et al. Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest 2000; 117:708-13.
5. Guilpain P, Viallard JF, Lagarde P, Cohen P, Kambouchner M, et al. Churg-Strauss syndrome in two patients receiving montelukast. Rheumatology 2002; 41:535-9.
6. Green RL, Vayonis AG. Churg-Strauss syndrome in two patients not receiving systemic steroid treatment. Lancet 1999; 353:725-6.
7. Robinson DS, Campbell D, Barnes BJ. Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial. Lancet 2001; 357:2007-11.
8. Garcia-Marcos L, Schuster A, Perez-Yarza EG. Benefit-risk assessment of antileukotrienes in the management of asthma. Drug Safety 2003; 26:483-518.
9. Munoz NM, Douglas I, Mayer D, Herrnreiter A, Zhu X, Leff AR. Eosinophil chemotaxis inhibited by 5-lipoxygenase blockade and leukotriene receptor antagonism. Am J Resp Crit Care Med 1997; 155:1398-403.
10. Donohue JF. Montelukast and Churg-Strauss Syndrome. Chest 2001; 119:668.
11. Keogh AK, Specks U. Churg-Strauss syndrome: Clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med 2003; 115:284-90.